# PROVIDERS' NEWS June 2020

Published for providers and their office staffs by Arkansas Blue Cross and Blue Shield • Editor: Sarah Ricard • 501 378 2150 • Fax: 501 378 2465 •

#### **TABLE OF CONTENTS**

ARKANSAS BLUE CROSS AND BLUE SHIELD		
2020 Spring Providers' Workshops	2	
COVID-19 update	2	
Changes to telehealth access for PT, OT, SLT, DC, DPM, RDN, BCBA & OD	6	
Answering providers' questions about our COVID-19 changes	7	
Coverage policy manual updates	10	
Federally required annual compliance training notice	12	
In-network laboratory reminder: correction	13	
Intra-fraction localization and tracking reported with HCPCS G6017	13	
MDLive	14	
Medical specialty prior approval medications update	14	
National drug codes required	18	
Standard formulary changes effective July 1, 2020	19	
Think twice before prescribing antibiotics for bronchitis	29	
HEDIS® NEWS		
Changes to the Controlling High Blood Pressure HEDIS Measure	31	
Statin therapy for patients with cardiovascular disease and diabetes	31	
FEP		
Smoking cessation tools	32	
Your path to a smoke-free future (flyer)		
One more reason to quit (flyer)		

### 2020 Spring Provider Workshop

In response to the COVID-19 pandemic, we have opted to produce a virtual video version of our annual Healthcare Provider Workshops instead of our traditional face-to-face gathering. Four videos are available for you to view at your convenience:

- General Network Update
- Medi-Pak® Advantage & Quality/Risk Updates
- COVID-19 Special Update
- AHIN to Availity transition information

Go to **2020 Spring Provider Workshop** to view the videos.

### COVID-19 update

Arkansas Blue Cross and Blue Shield and Health Advantage described a temporary change to our policy in the March issue of Arkansas Blue Cross *Providers' News*. We revised that temporary policy on March 24, 2020, making it retroactive to March 16, 2020. The changes will be in effect through at least July 25, 2020, and could be extended beyond that date, if circumstances warrant. This update provides additional clarity to what was published on March 24.

This revision applies to fully-insured Arkansas Blue Cross and Health Advantage plans including Individual Metallic Exchange Plans. It does not necessarily apply to any self-funded plan (like Walmart, Tyson Foods, or J.B. Hunt, etc.) because each of those plan-sponsors decides their own telehealth coverage policy. The Arkansas State Employees/Public School Employees have opted in to these temporary policy changes regarding telemedicine. You should contact the customer service departments for FEP and out-of-state BlueCard plans for their policy on telehealth services and how benefits will be applied.

No copays, coinsurance, or deductibles will be applied to the allowances for CPT codes where noted. If you have questions, please contact your Arkansas Blue Cross Network Development Representative (NDR). Click <a href="https://here">here</a> for your NDR contact information.

Any of the submitted codes are still subject to contractual limitations, coverage criteria and any applicable payment edits.

All are independent licensees of the Blue Cross Blue Shield Association.

Providers' News / June 2020 (Page 2 of 36)

## Telemedicine Codes approved in response to the COVID-19 pandemic for in-network providers seeing ABCBS fully-insured members (BC, HA, and Metallic) for the duration of March 16, 2020 through July 25, 2020

1) No cost share: The below codes may be billed by MD/DOs and APRN/CNP/CNW/PAs.

#### The below codes require modifier -95 or -GT and POS 02

- 99201 Office or other outpatient visit for the evaluation and management of a new patient. Usually, the presenting problem(s) are self-limited or minor. Typically, 10 minutes are spent face to face with the patient and/or family.
- 99202 Office or other outpatient visit for the evaluation and management of a new patient. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent face to face with the patient and/or family.
- 99203 Office or other outpatient visit for the evaluation and management of a new patient, Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face to face with the patient and/or family.
- 99204 Office or other outpatient visit for the evaluation and management of a new patient. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face to face with the patient and/or family.
- 99211 Office or other outpatient visit for the evaluation and management of an established patient. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.
- 99212 Office or other outpatient visit for the evaluation and management of an established patient. Usually, the presenting problem(s) are self-limited or minor. Typically, 10 minutes are spent face to face with the patient and/or family.
- 99213 Office or other outpatient visit for the evaluation and management of an established patient. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face to face with the patient and/or family.
- 99214 Office or other outpatient visit for the evaluation and management of an established patient. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face to face with the patient and/or family.

All are independent licensees of the Blue Cross Blue Shield Association.

(Page 3 of 36)

Providers' News / June 2020

2) No cost share: The below codes may be billed by clinical psychologists (PhD/PsyD/EdD), licensed psychological examiners (LPE), advance nurse practitioners (APNs) with psychiatric certification, licensed clinical social workers (LCSWs), licensed professional counselors (LPCs), and physicians (MDs and DOs).

The below codes must be billed with modifier -95 or -GT and POS 02

- 90791 Psychiatric diagnostic evaluation
- 90792 Psychiatric diagnostic evaluation with medical services
- 90832 Psychotherapy, 30 minutes with patient
- **90833** Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure.)
- 90834 Psychotherapy, 45 minutes with patient
- **90836** Psychotherapy, 45 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure.)
- 90837 Psychotherapy, 60 minutes with patient
- **90838** Psychotherapy, 60 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure.)
- 90845 Psychoanalysis
- 90846 Family psychotherapy (without the patient present), 50 minutes
- 90847 Family psychotherapy (conjoint psychotherapy) (with patient present), 50 minutes
- 3) No cost share: The below codes may be billed by clinical psychologists (PhD/PsyD/EdD), licensed Psychological examiners (LPE), advance nurse practitioners (APNs) with/without psychiatric certification, certified nurse practitioners (CNP), certified nurse midwives (CNW), physician assistants (PAs), licensed clinical social workers (LCSWs), licensed professional counselors (LPCs), and physicians (MDs and DOs).

#### The below codes must be submitted with POS 02.

- **99421** Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5–10 minutes
- **99422** Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11–20 minutes
- **99423** Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 21 or more minutes

Providers' News / June 2020 (Page 4 of 36)

- 99441 Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5–10 minutes of medical discussion
- 99442 Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11–20 minutes of medical discussion
- 99443 Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21–30 minutes of medical discussion

The Arkansas Blue Cross and Blue Shield coverage policy 2015034 remains in effect. Providers noted in the coverage policy may continue to submit claims as described in the policy for other codes. These claims and codes will be subject to copay, coinsurance, and deductible.

- 4) No cost share applied to the following Neuropsychological testing codes when performed by innetwork Psychologist, Psychological Examiners or MD/DO. Codes must be submitted with place of service 02 and modifier –95 or –GT to indicate billing of a telehealth service. However, all other contractual limitations will still apply.
  - 96132 Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour
  - 96136 Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes
  - **96138** Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes
  - 96139 Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)

Providers' News / June 2020 (Page 5 of 36)

Again, if you have questions, please contact your Arkansas Blue Cross Network Development Representative at this link: <a href="https://www.arkansasbluecross.com/providers/resource-center/network-development-reps">https://www.arkansasbluecross.com/providers/resource-center/network-development-reps</a>. This information is also available on AHIN.

# Changes to telehealth access for PT, OT, SLT, DC, DPM, RDN, BCBA & OD during pandemic\*

To further assist our members and providers in their efforts to practice social distancing, Arkansas Blue Cross and Blue Shield and Health Advantage are making additional temporary changes in benefits by allowing their fully insured members telemedicine access to in network providers delivering specific services by physical therapists, occupational therapists, speech and language therapists, chiropractors, podiatrists, registered dieticians, board certified behavioral analysts and optometrists. There will be no waiver of cost share (e.g. copays, deductibles, and coinsurance) for these services, and all contractual limitations, conditions, policies, and procedures will apply.

Arkansas Blue Cross and Health Advantage have voluntarily increased overall compensation for telemedicine services for fully insured members by reimbursing all such services at the "office" level. This payment enhancement became effective for these specific services rendered beginning April 1, and will continue through July 25, 2020.

Codes must be submitted with place of service 02 and modifier 95 or GT to indicate billing of a telehealth service. Appropriate documentation commensurate with the level of service provided and submitted for payment is to be placed in the medical record.

Providers are responsible for ensuring that they are in compliance with Arkansas law for their specialty regarding telemedicine.

Only the following codes will be reimbursed for telemedicine. Telephonic codes do not apply.

**Physical Therapy (PT)**—97161, 97162, 97163, 97164, 97110, 97112, 97116, 97535

Occupational Therapy (OT)—97165, 97166, 97167, 97168, 97110, 97112, 97116, 97535, 92523

**Speech & Language Therapy (SLT)**—92507, 92521, 92522, 92523, 92524, 92526, 92610, 96105, 97110

Chiropractic Medicine (DC)—99201, 99202, 99203, 99204, 99211, 99212, 99213, 99214 (used for initial evaluation or re-evaluation when submitted without a manipulation code)

Podiatric Medicine (DPM)—99201, 99202, 99203, 99204, 99211, 99212, 99213, 99214

**Registered Dieticians (RDN)**—97802, 97803, 97804, G0108, G0109

#### Board Certified Behavioral Analyst—

- 97153, 97155, 97156 (these services will be subject to coverage policy 2017002, only 50% services hours can be performed by telemedicine, subject to prior approval guidelines.)
- 97151, 97152 (these services will be subject to coverage policy 2011053, subject to prior approval guidelines.)

**Optometrists**—99201, 99202, 99203, 99204, 99211, 99212, 99213, & 99214 (Specialty 41).

\*This article originally appeared in the April 13, 2020, special issue of *Providers' News*.

# Answering providers' questions about our COVID-19 changes\*

#### **Telemedicine**

Will Arkansas Blue Cross and Health Advantage cover telemedicine, including video and telephone calls for providers at in-clinic rates?

Yes. To further assist providers in their efforts to practice social distancing to reduce risks of exposure to COVID-19, Arkansas Blue Cross and Blue Shield and Health Advantage voluntarily increased overall compensation for telemedicine services for fully insured members by reimbursing all such services at the "office" level. This payment enhancement became effective for services rendered beginning March 16, and will continue through July 25, at which time the policy will be revisited. All providers must be in network which include physicians (MDs and DOs), advance practice nurse practitioners, physician assistants and behavioral health professionals (in-network psychiatrist, clinical psychologist, advance practice nurse practitioner, licensed clinical social worker, licensed psychological examiner, or licensed professional counselor). Appropriate documentation commensurate with the level of service provided and submitted for payment is to be placed in the medical record.

All are independent licensees of the Blue Cross Blue Shield Association.

Providers' News / June 2020 (Page 7 of 36)

#### Can telemedicine be used for wellness visits?

Yes, physicians (MDs and DOs), advance practice nurse practitioners, and physician assistants can use telemedicine for wellness/preventative visits. Appropriate documentation commensurate with the level of service provided and submitted for payment is to be placed in the medical record. Providers may submit all of the wellness/preventative visit codes ranging from 99381 through 99397. Claims should be billed with POS 02 and either the GT or 95 modifiers.

#### What codes should I use if I am seeing my patients virtually, either by audiovisual or telephone appointments?

Physicians (MDs and DOs), advance practice nurse practitioners, physician assistants and behavioral health professionals who are seeing patients virtually either with audiovisual or telephone should use the telemedicine CPT (E&M) codes, not the telephonic CPT codes. Providers may submit the E&M codes <u>listed here</u>. Claims should be billed with POS 02 and either the GT or 95 modifiers.

#### Are HIPAA-defined secure video requirements relaxed for telemedicine during the pandemic?

Yes. You do not have to have secure video for telemedicine and can use any type of telephone (without video) or any video connection. These will be reimbursed at the telemedicine rate. Physicians (MDs and DOs), advance practice nurse practitioners, physician assistants and behavioral health professionals who are seeing patients virtually either with audiovisual or telephone should use the telemedicine policy CPT (E&M) codes listed here, not the telephonic CPT codes.

## Are copays, coinsurance and deductibles waived for fully insured members for video or telephone-based doctor's visits? Does this include behavioral health?

Yes. We will waive all copays, coinsurance, and deductibles for medical care administered by telemedicine by in-network physicians (MDs and DOs), advance practice nurse practitioners, physician assistants and behavioral health professionals (see complete list <a href="here">here</a>). This is for medical care, not just COVID-19 related issues. We will pay the lesser of billed charge or contract allowance. Telemedicine is also available for other therapies, but cost-shares and co-pays do apply.

#### Does the temporary in-office rate for telemedicine coverage include mental/behavioral health?

Yes. We will pay for telemedicine counseling using the specific CPT codes listed <u>above</u>, by video or over the telephone, for our fully insured members by any in-network behavioral health professionals (in-network psychiatrist, clinical psychologist, advance practice nurse practitioner, licensed clinical social worker, licensed psychological examiner, or licensed professional counselor). This is being provided at no cost share to the member. Behavioral health professionals who are seeing patients virtually either with audiovisual or telephone should use the telemedicine CPT (E&M) codes <u>listed here</u>, not the telephonic CPT codes.

#### What other types of therapies are covered by the temporary in-office rate?

At this time, only behavioral/mental health is covered via telemedicine, in addition to physician-administered medical care from MDs and DOs. Providers should access AHIN for specific coverage information.

Telemedicine is also available for other therapies, but cost-shares and co-pays do apply. See **this article** for more information.

#### **COVID-19 Testing Costs**

Will Arkansas Blue Cross and Health Advantage cover COVID-19 specific testing at no cost to members? What about additional testing for flu or strep?

Yes. We will cover the testing by in-network providers to diagnose COVID-19. The only recommended definitive test for COVID-19 is the RT-PCR test (CPT Code 87635) which involves swabbing the nose and/or mouth. If an influenza or group A Streptococcus bacteria test are administered as part of the COVID-19 testing, they will be paid as well. The influenza CPT Codes are 87804 and 86710 and the group A Streptococcus bacteria CPT Codes is 87880. This change will be retroactive to March 16. These claims should be submitted with the modifier "CS."

#### Will virtual or physical visits for COVID-19 testing be covered if a patient does not get tested?

Yes. We will cover COVID-19 evaluation visits without cost share if submitted with the modifier "CS" even if a COVID-19 test was not done, but the intent of the visit was to evaluate the member for COVID testing, not an unrelated medical condition (e.g. diabetes, hypertension, etc.)

#### **COVID-19 Specific Treatment**

Will Arkansas Blue Cross and Health Advantage waive patient cost sharing for all COVID-19 treatment? We will waive cost sharing (copay, coinsurance, deductible) for our fully insured members for a visit to a medical clinic, urgent care facility and emergency room, as well as inpatient treatment when there is a COVID-19 primary diagnosis. A visit that involves treatment or testing not related to COVID-19 will be subject to cost sharing.

This adjustment in coverage will be effective from April 1, through July 25, 2020, at which time it will be reevaluated. Any claim for COVID-19 evaluation should include a "CS" modifier and include the ICD-10 diagnostic code of U07.1. The waiver also will apply to ACIP-approved vaccines when they become available.

Does this include emergency transport for fully insured members to designated quarantine or treatment centers? We will cover emergency/ambulance services in accordance with and subject to the limitations of a member's insurance policy. Transportation solely for quarantine purposes (rather than treatment) would not be covered, and most insurance policies limit the amount of benefits available for both ground and air ambulance services.

All are independent licensees of the Blue Cross Blue Shield Association.

#### **Early Prescription Refills Allowed**

Will you waive prescription quantity/supply limits or allow for early refills to enable members to stock up on prescription maintenance medication due to shortages caused by COVID-19?

Yes. Our fully insured members can request early prescription refills, up to 90 days, on most maintenance medications. We also allow for flexibility in our prescription drug formulary if there are medication shortages or access issues.

#### **Prior Authorizations / Pre-certifications Suspended**

Will Arkansas Blue Cross and Health Advantage suspend prior authorizations and pre-certifications for insured members for hospital inpatient, outpatient and ambulatory surgery centers?

Yes. We are temporarily stopping prior authorizations and pre-certifications for hospital inpatient, outpatient and ambulatory surgery centers for our fully insured members through July 25, 2020, at which time this temporary policy will be re-evaluated. This change does not apply to prior authorizations for prescription and specialty medication, high-tech radiology services or long-term acute-care hospitals.

While prior approvals are temporarily stopped, we still require a call so our care management teams can support members being transitioned to their homes. For outpatient procedures, you will continue to receive system-generated medical record requests, but you may disregard them. This does not guarantee coverage of services rendered.

When you call, our intake team will let you know if the patient is covered under a plan that does not require prior approvals. If the patient's plan requires prior approvals, you must provide the medical information requested for the services to be covered.

\*This article was originally published in the April 2020 special issue of *Providers' News* and has been updated.

## **Coverage Policy manual updates**

Since March 2020, Arkansas Blue Cross has added or updated several policies in its Coverage Policy manual. The table below highlights these additions and updates. If you want to view entire policies, you can access the coverage policies located on our website at <u>arkansasbluecross.com</u>.

All are independent licensees of the Blue Cross Blue Shield Association.

Providers' News / June 2020 (Page 10 of 36)

Policy ID	Policy Name
2015014	Amniotic Membrane and Amniotic Fluid Injections
2016005	, , , , , , , , , , , , , , , , , , ,
2011053	
2017006	Bevacizumab (Avastin™) for Oncologic Indications
2018024	Burosumab-twza (Crysvita®)
2010000	Capsaicin (Qutenza) for the Treatment of Post-Herpetic Neuralgia
2016013	CD 5 Complement Inhibitors
2018002	Chemodenervation, Botulinum Toxins
1997036	Cognitive Rehabilitation
2005010	
2017026	
2014026	
2010005	,
	Neuromodulation Therapy (PNT)
1998168	Etanercept (Enbrel)
2018021	Gene Therapy for Inherited Retinal Dystrophy-Voretigene (Luxturna)
1998051	Genetic Test: BRCA1 or BRCA2 Mutations
2015004	Genetic Test: Breast Cancer Risk Assessment (PALB2, CHEK2, ATM)
2003018	Genetic Test: Fecal DNA to Detect Colorectal Cancer, Screening
2007024	
1997087	
2017034	
1997105	
1998095	
1998112	
2010046	
2011006	
2003024	
2018000	Leadless Cardiac Pacemakers
2018023	
1997126	
2016010	
2015024	
2018025	
2017033	
2017014 2016021	Olaratumab (LARTRUVO™) Paliperidone Palmitate (Long-acting Injectables Invega Sustenna ® & Invega Trinza)
2019005	Pembrolizumab (KEYTRUDA®)
2000001	PET or PET/CT for Colorectal Cancer
2000001	PET or PET/CT for Melanoma
1998156	PET of PET/CT for Melanoma  PET or PET/CT for Non-Small Cell Lung Cancer
2001038	PET or PET/CT for Pancreatic Cancer
2001035	PET or PET/CT for Prostate Cancer
2011020	Preventive services for non-grandfathered (PPACA) plans: Bacteriuria screening in pregnant
2011020	women
2011066	Preventive services for non-grandfathered (PPACA) plans: Overview
2003022	Radioimmunoscintigraphy Imaging - Indium-111 Capromab Pendetide (ProstaScint)

Providers' News / June 2020 (Page 11 of 36)

Policy ID	Policy Name
2009040	Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
2013048	Repository Corticotropin Injection
2006016	Rituximab (Rituxan)
2012030	Sinus Spacers, Stents, and Implants, following Endoscopic Sinus Surgery
2012009	Skin and Soft Tissue Substitutes, Bio-Engineered Products
2015035	Sleep Apnea, Minimally Invasive Surgical Treatment
1997137	Strontium 89, Metastron
2013030	Teduglutide (GATTEX®) for Short Bowel Syndrome (SBS)
2015034	Telemedicine
2015028	Testosterone Replacement Therapy
2016008	Thermal Ablation of Peripheral Nerves to Treat Pain Associated with Plantar Fasciitis, Knee
	Osteoarthritis, Sacroiliitis and Other Conditions
2014017	Transcatheter Mitral Valve Repair
2013015	Treatment of Varicose Veins/Venous Insufficiency
2015011	Vedolizumab (Entyvio) for Inflammatory Bowel Disease
1999012	Vertebroplasty, Percutaneous
1998119	Viscosupplementation for the Treatment of Osteoarthritis of the Hip, Knee, and All Other Joints

### Federally required annual compliance training notice

Arkansas Blue Cross and Blue Shield is required by the federal government to ensure that certain individuals and entities with whom we do business (including healthcare-related professionals and organizations) complete general compliance training and fraud, waste and abuse training annually. This year, the training will be released in the fall.

#### Who must complete training?

General compliance training and fraud, waste and abuse training (where applicable), should be completed annually by **all persons** who have contact (indirect or direct) with beneficiaries of the federal Centers for Medicare & Medicaid Services (CMS) and members covered by the Affordable Care Act. This includes staff in all billing, reception, lab and clinical areas.

General compliance training is required for all persons who meet the above criteria, but certain individuals and entities who participate in the Medicare program are deemed to have met the **fraud**, **waste and abuse** training component by virtue of satisfying Medicare's annual certification requirements. This includes entities and/or individuals who are:

- Participating healthcare providers in the federal Medicare program (Parts A and/or B).
- Accredited, Medicare-approved suppliers of durable medical equipment, prosthetics, orthotics and supplies.

All are independent licensees of the Blue Cross Blue Shield Association.

Providers' News / June 2020 (Page 12 of 36)

#### When should training be complete?

The general compliance training and/or fraud, waste and abuse training must occur within 90 days of initial hiring and annually thereafter. The annual training will be released September 2020 and must be completed by the end of the calendar year. Training must be documented, and all documentation is subject to random audit by Arkansas Blue Cross or the federal government.

Direct any questions to <u>regulatorycompliance@arkbluecross.com</u>.

### In-network laboratory reminder: correction

Please note a correction to the March 2020 Providers' News "In-network laboratory reminder" article.

The last paragraph should read, "If an out-of-network laboratory is used, members **are** financially responsible for all services not paid by the health plan."

## Intra-fraction localization and tracking reported with HCPCS G6017

Arkansas Blue Cross and Blue Shield has updated Coverage Policy 2009001 which addresses Real Time Intra-Fraction Target Tracking to add coverage of real-time intra-fraction localization when used with deep inspiration breath-hold irradiation for the treatment of left-sided breast cancer to minimize negative side effects from radiation therapy. The intra-fraction localization is expected to be billed with HCPCS G6017. When this procedure is used with IMRT, the technical component of the code is bundled with the IMRT delivery code so we would expect only the professional component to be billed. When used with conventional or 3D conformal radiation, the global code is appropriate in the freestanding setting. In the hospital, only the professional component should be billed.

The rationale for this change and the complete Coverage Policy can be accessed at the following link: https://secure.arkansasbluecross.com/members/report.aspx?policyNumber=2009001.

All are independent licensees of the Blue Cross Blue Shield Association.

Providers' News / June 2020 (Page 13 of 36)

## **MDLive**

Arkansas Blue Cross and Blue Shield and its family of companies have chosen MDLive as a telehealth option for its fully-insured clients. Click <a href="here">here</a> for more information about joining the MDLive team. MDLive has partnered with Arkansas Blue Cross to expedite onboarding and credentialing.

Medical specialty prior approval medications update

On April 1, 2018, Arkansas Blue Cross and Blue Shield and its family of companies enacted prior approval for payment of specialty medications used in treating rare, complex conditions that may go through the medical benefit. Since then, medications have been added to the initial list as products come to market.

The table below is the current list of medications that require prior approval through the member's medical benefit. **ASE/PSE** and **Medicare are not included in this prior approval (PA) program**. It is also indicated when a medication is required to be processed through the pharmacy benefit. Any new medication used to treat a rare disease should be considered to require prior approval.

Drug	Indication	Benefit
Adakveo	Sickle cell disease	Medical
(crizanlizumab-tcma)		
Aldurazyme	MPS I	Medical
(laronidase)	Hurler syndrome	
Berinert	Hereditary angioedema	Medical
(c1 esterase, inhib, human)		
Brineura	CLN2 disease	Medical
(ceroliponase alfa)		
	Thrombocytic	
Cablivi	thrombocytopenia	Medical & Pharmacy
(caplacizumab-yhdp)		
Cinqair	Severe asthma	Medical
(reslizumab)		

All are independent licensees of the Blue Cross Blue Shield Association.

Providers' News / June 2020 (Page 14 of 36)

Cinryze (c1 Esterase, inhib, human)  Crysvita Hypophosphatemia Pharmacy (burosumab - twza)  Duopa Parkinson's Medical (levodopa-carpidopa intestinal gel)  Elaprase MPS II Medical (idursulfase) Hunter syndrome  Elzonris BPDCN Medical (tagraxifusp-erzs)  Evenity Severe osteoporosis Medical (romosozumab-aqqg)  Fabrazyme Fabry disease Medical (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant (mappalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (cecallantide)  Krystexxa Gout Medical  Medical  Medical  Medical  Pharmacy			
(c1 Ésterase, inhib, human)       Hypophosphatemia       Pharmacy         Crysvita       Hypophosphatemia       Pharmacy         (burosumab - twza)       Parkinson's       Medical         Duopa (levodopa-carpidopa intestinal gel)       MPS II       Medical         Elaprase (idursulfase)       Hunter syndrome       Medical         Elzonris (tagraxifusp-erzs)       BPDCN       Medical         Evenity (romosozumab-aqqg)       Severe osteoporosis       Medical         Fabrazyme (agalsidase beta)       Fabry disease       Medical         Fasenra (benralizumab)       Mod to severe asthma       Pharmacy         Firazyr (benralizumab)       Hereditary angioedema       Pharmacy         Firazyr (icatabant acetate)       Hereditary angioedema       Medical         Gamifant (emapalumab-lzsg)       Acute hepatic porphyria       Medical         Givlaari (givosiran)       Acute hepatic porphyria (givosiran)       Medical         Haegarda (c1 esterase, inhib, human)       Hereditary angioedema       Pharmacy         Krystexxa       Gout       Medical	Cinryze	Hereditary andioedema	Medical
Crysvita (burosumab - twza)  Duopa (levodopa-carpidopa intestinal gel)  Elaprase (idursulfase) Hunter syndrome  Elzonris (tagraxifusp-erzs)  Evenity (romosozumab-aqqg)  Fabrazyme Fabry disease Medical (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant (emapalumab-lzsg)  Givlaari (givosiran)  Haegarda (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  Krystexxa Gout Medical  Pharmacy Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Pharmacy  Pharmacy		Thereditary anglocuema	iviedicai
Duopa   Parkinson's   Medical	(6.7		
Duopa   Parkinson's   Medical	Crysvita	Hypophosphatemia	Pharmacy
(levodopa-carpidopa intestinal gel)  Elaprase MPS II Medical (idursulfase) Hunter syndrome  Elzonris BPDCN Medical (tagraxifusp-erzs)  Evenity Severe osteoporosis Medical (romosozumab-aqqg)  Fabrazyme Fabry disease Medical (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohisticcytosis Medical (givosiran)  Givlaari (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical Medical	(burosumab - twza)		
(levodopa-carpidopa intestinal gel)  Elaprase MPS II Medical (idursulfase) Hunter syndrome  Elzonris BPDCN Medical (tagraxifusp-erzs)  Evenity Severe osteoporosis Medical (romosozumab-aqqg)  Fabrazyme Fabry disease Medical (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohisticcytosis Medical (givosiran)  Givlaari (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical Medical			
Elaprase MPS II Medical  (idursulfase) Hunter syndrome  Elzonris BPDCN Medical  (tagraxifusp-erzs)  Evenity Severe osteoporosis Medical  (romosozumab-aqqg)  Fabrazyme Fabry disease Medical  (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy  (benralizumab)  Firazyr Hereditary angioedema Pharmacy  (icatabant acetate)  Hemophagocytic Iymphohistiocytosis Medical  Gamifant Iymphohistiocytosis Medical  Givlaari Acute hepatic porphyria Medical  (givosiran)  Haegarda Hereditary angioedema Pharmacy  (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  (ecallantide)  Krystexxa Gout Medical		Parkinson's	Medical
Elaprase (idursulfase) Hunter syndrome  Elzonris BPDCN Medical  Evenity Severe osteoporosis Medical  Fabrazyme (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy  (benralizumab)  Firazyr Hereditary angioedema Pharmacy  (icatabant acetate)  Gamifant Iymphohistiocytosis Medical  Givlaari Acute hepatic porphyria Medical  (givosiran)  Haegarda (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  Fharmacy Medical  Medical  Medical  Medical  Medical  Medical  Pharmacy  Pharmacy  Medical  Pharmacy  Pharmacy  Medical  Pharmacy  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Pharmacy  Medical  Medical  Medical  Medical  Medical			
(idursulfase)       Hunter syndrome         Elzonris       BPDCN       Medical         (tagraxifusp-erzs)       Medical         Evenity       Severe osteoporosis       Medical         (romosozumab-aqqg)       Fabry disease       Medical         Fabrazyme       Fabry disease       Medical         (agalsidase beta)       Pharmacy         Firasenra       Mod to severe asthma       Pharmacy         Firazyr       Hereditary angioedema       Pharmacy         (icatabant acetate)       Hemophagocytic         (gramifant       lymphohistiocytosis       Medical         (emapalumab-lzsg)       Acute hepatic porphyria       Medical         Givlaari       Acute hepatic porphyria       Medical         Haegarda       Hereditary angioedema       Pharmacy         (c1 esterase, inhib, human)       Hereditary angioedema       Pharmacy         Kalbitor       Hereditary angioedema       Pharmacy         Krystexxa       Gout       Medical	intestinal gel)		
(idursulfase)       Hunter syndrome         Elzonris       BPDCN       Medical         (tagraxifusp-erzs)       Medical         Evenity       Severe osteoporosis       Medical         (romosozumab-aqqg)       Fabry disease       Medical         Fabrazyme       Fabry disease       Medical         (agalsidase beta)       Pharmacy         Firasenra       Mod to severe asthma       Pharmacy         Firazyr       Hereditary angioedema       Pharmacy         (icatabant acetate)       Hemophagocytic         (gramifant       lymphohistiocytosis       Medical         (emapalumab-lzsg)       Acute hepatic porphyria       Medical         Givlaari       Acute hepatic porphyria       Medical         Haegarda       Hereditary angioedema       Pharmacy         (c1 esterase, inhib, human)       Hereditary angioedema       Pharmacy         Kalbitor       Hereditary angioedema       Pharmacy         Krystexxa       Gout       Medical	Flanrase	MPS II	Medical
Elzonris (tagraxifusp-erzs)  Evenity Severe osteoporosis Medical (romosozumab-aqqg)  Fabrazyme Fabry disease Medical (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Hemophagocytic lymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical			Wicalcai
Evenity Severe osteoporosis Medical (romosozumab-aqqg)  Fabrazyme Fabry disease Medical (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (givosiran)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical		2,112,121	
Evenity Severe osteoporosis Medical (romosozumab-aqqg)  Fabrazyme Fabry disease Medical (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical	Elzonris	BPDCN	Medical
Fabrazyme Fabry disease Medical  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical	(tagraxifusp-erzs)		
Fabrazyme Fabry disease Medical  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical			
Fabrazyme (agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical		Severe osteoporosis	Medical
(agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical	(romosozumab-aqqg)		
(agalsidase beta)  Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical	Cabrazuma	Fahry diagona	Madical
Fasenra Mod to severe asthma Pharmacy (benralizumab)  Firazyr Hereditary angioedema Pharmacy (icatabant acetate)  Gamifant Iymphohistiocytosis Medical (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical		Fabi y disease	Medical
(icatabant acetate)  Hemophagocytic lymphohistiocytosis  Givlaari Acute hepatic porphyria Medical  Haegarda Hereditary angioedema Pharmacy  (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  (ecallantide)  Krystexxa Gout Medical	(agaisidase beta)		
(icatabant acetate)  Hemophagocytic lymphohistiocytosis  Givlaari Acute hepatic porphyria Medical  Haegarda Hereditary angioedema Pharmacy  (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  (ecallantide)  Krystexxa Gout Medical	Fasenra	Mod to severe asthma	Pharmacy
(icatabant acetate)  Hemophagocytic Iymphohistiocytosis  Givlaari (givosiran)  Haegarda (c1 esterase, inhib, human)  Kalbitor (ecallantide)  Krystexxa  Gout  Hemophagocytic Iymphohistiocytosis  Medical  Medical  Medical  Pharmacy  Pharmacy  Medical	(benralizumab)		
(icatabant acetate)  Hemophagocytic lymphohistiocytosis Medical  Gamifant lymphohistiocytosis Medical  Givlaari Acute hepatic porphyria Medical  (givosiran)  Haegarda Hereditary angioedema Pharmacy  (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  (ecallantide)  Krystexxa Gout Medical			
Gamifant Iymphohistiocytosis Medical  Givlaari Acute hepatic porphyria Medical  (givosiran)  Haegarda Hereditary angioedema Pharmacy  (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  (ecallantide)  Krystexxa Gout Medical		Hereditary angioedema	Pharmacy
Gamifant lymphohistiocytosis Medical  (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical  (givosiran)  Haegarda Hereditary angioedema Pharmacy  (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  (ecallantide)  Krystexxa Gout Medical	(icatabant acetate)		
Gamifant lymphohistiocytosis Medical  (emapalumab-lzsg)  Givlaari Acute hepatic porphyria Medical  (givosiran)  Haegarda Hereditary angioedema Pharmacy  (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy  (ecallantide)  Krystexxa Gout Medical		Llamanhagaaytia	
Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical	Camifant		Medical
Givlaari Acute hepatic porphyria Medical (givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical		lymphomstiocytosis	iviedicai
(givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical	(Sinapaidinas 1209)		
(givosiran)  Haegarda Hereditary angioedema Pharmacy (c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical	Givlaari	Acute hepatic porphyria	Medical
(c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical			
(c1 esterase, inhib, human)  Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical			
Kalbitor Hereditary angioedema Pharmacy (ecallantide)  Krystexxa Gout Medical		Hereditary angioedema	Pharmacy
(ecallantide)  Krystexxa  Gout  Medical	(c1 esterase, inhib, human)		
(ecallantide)  Krystexxa  Gout  Medical	Kalhitor	Hereditary angioedema	Dharmaou
Krystexxa Gout Medical		ricieulary angloedema	riiaiiiiacy
	(Codification)		
	Krystexxa	Gout	Medical

Providers' News / June 2020 (Page 15 of 36)

(tisagenlecleucel)  Lemtrada (alemtuzumab)  Lutathera (lutetium Lu 177 Dotatate)  Megsevii (vestronidase-Alfa) Siy syndrome  Myalept (lipodystrophy Pharmacy (galsulfase) Maroteaux-Lamy syndrome  Nucala (mepolizumab)  Ruconest Hereditary angioedema Medical  (c1 esterase, inhib, recombinant)  Soliris PNH Medical  (eculizumab) AlfuS  Spinraza (nusinersen)  Spravato (esketamine)  Strensiq (asfotase alfa)  Tepezza Thyroid eye disease Medical	Kymriah	Cancers	Medical
(alemtuzumab)       Neuroendocrine tumors       Medical         (lutetium Lu 177 Dotatate)       MPS VII       Medical         Mepsevii       MPS VII       Medical         (vestronidase-Alfa)       Sly syndrome         Myalept       Lipodystrophy       Pharmacy         (metreleptin)       Medical         Nagalzyme       MPS VI       Medical         (galsulfase)       Maroteaux-Lamy syndrome         Nucala       Mod to severe asthma       Pharmacy         (mepolizumab)       Hereditary angioedema       Medical         (c1 esterase, inhib, recombinant)       PNH       Medical         Soliris       PNH       Medical         (eculizumab)       aHUS       Medical         Myasthenia Gravis       NMOSD       Medical         Spinraza       Spinal muscle atrophy       Medical         (nusinersen)       Treatment resistant depression       Pharmacy         Strensiq       Hypophosphatasia       Pharmacy         (asfotase alfa)       Thyroid eye disease       Medical         Ultomiris       PNH       Medical	(tisagenlecleucel)		*Reviewed by Transplant Coordinator
(alemtuzumab)       Neuroendocrine tumors       Medical         (lutetium Lu 177 Dotatate)       MPS VII       Medical         Mepsevii       MPS VII       Medical         (vestronidase-Alfa)       Sly syndrome         Myalept       Lipodystrophy       Pharmacy         (metreleptin)       Medical         Nagalzyme       MPS VI       Medical         (galsulfase)       Maroteaux-Lamy syndrome         Nucala       Mod to severe asthma       Pharmacy         (mepolizumab)       Hereditary angioedema       Medical         (c1 esterase, inhib, recombinant)       PNH       Medical         Soliris       PNH       Medical         (eculizumab)       aHUS       Medical         Myasthenia Gravis       NMOSD       Medical         Spinraza       Spinal muscle atrophy       Medical         (nusinersen)       Treatment resistant depression       Pharmacy         Strensiq       Hypophosphatasia       Pharmacy         (asfotase alfa)       Thyroid eye disease       Medical         Ultomiris       PNH       Medical	Lauretra da	Maritinia Octobrila	Madiaal
Lutathera (lutetium Lu 177 Dotatate)  Mepsevii MPS VII Medical (vestronidase-Alfa)  Myalept Lipodystrophy Pharmacy (metreleptin)  Nagalzyme MPS VI Medical (galsulfase)  Nucala Mod to severe asthma Pharmacy (mepolizumab)  Ruconest (c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab)  Spinraza (eculizumab)  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical  Medical (Pharmacy Medical Pharmacy (Medical Pharmacy Medical Pharmacy (Medical Pharmacy Medical Pharmacy Medical Pharmacy (Medical Pharmacy Medical Pharmacy (Medical Pharmacy Medical Pharmacy (Medical Pharmacy Medical Pharmacy Medical Pharmacy (Medical Medical		Multiple Scierosis	Medical
(lutetium Lu 177 Dotatate)  Mepsevii MPS VII Medical (vestronidase-Alfa) Sly syndrome  Myalept Lipodystrophy Pharmacy (metreleptin)  Nagalzyme MPS VI Medical (galsulfase) Maroteaux-Lamy syndrome  Nucala Mod to severe asthma Pharmacy (mepolizumab)  Ruconest Hereditary angioedema Medical (c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab) AHUS Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical	(alemuzumab)		
(lutetium Lu 177 Dotatate)  Mepsevii MPS VII Medical (vestronidase-Alfa) Sly syndrome  Myalept Lipodystrophy Pharmacy (metreleptin)  Nagalzyme MPS VI Medical (galsulfase) Maroteaux-Lamy syndrome  Nucala Mod to severe asthma Pharmacy (mepolizumab)  Ruconest Hereditary angioedema Medical (c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab) AHUS Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical	Lutathera	Neuroendocrine tumors	Medical
(vestronidase-Alfa)       Sly syndrome         Myalept (metreleptin)       Lipodystrophy       Pharmacy         Nagalzyme (galsulfase)       MPS VI Maroteaux-Lamy syndrome         Nucala (mepolizumab)       Mod to severe asthma       Pharmacy         Ruconest (c1 esterase, inhib, recombinant)       Hereditary angioedema       Medical         Soliris (eculizumab)       PNH Medical       Medical         Spinraza (rousinaza (nusinersen)       Spinal muscle atrophy       Medical         Spravato (esketamine)       Treatment resistant depression       Pharmacy         Strensiq (asfotase alfa)       Hypophosphatasia       Pharmacy         Tepezza (teprotumumab)       Thyroid eye disease       Medical         Ultomiris       PNH Medical			
(vestronidase-Alfa)       Sly syndrome         Myalept (metreleptin)       Lipodystrophy       Pharmacy         Nagalzyme (galsulfase)       MPS VI Maroteaux-Lamy syndrome         Nucala (mepolizumab)       Mod to severe asthma       Pharmacy         Ruconest (c1 esterase, inhib, recombinant)       Hereditary angioedema       Medical         Soliris (eculizumab)       PNH Medical       Medical         Spinraza (rousinaza (nusinersen)       Spinal muscle atrophy       Medical         Spravato (esketamine)       Treatment resistant depression       Pharmacy         Strensiq (asfotase alfa)       Hypophosphatasia       Pharmacy         Tepezza (teprotumumab)       Thyroid eye disease       Medical         Ultomiris       PNH Medical			
Myalept (metreleptin)  Nagalzyme (MPS VI Medical (galsulfase)  Nucala Mod to severe asthma Pharmacy (mepolizumab)  Ruconest (c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab)  Spinraza (musinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia PNH Medical (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical			Medical
(metreleptin)       Nagalzyme       MPS VI       Medical         (galsulfase)       Maroteaux-Lamy syndrome         Nucala       Mod to severe asthma       Pharmacy         (mepolizumab)       Pharmacy         Ruconest       Hereditary angioedema       Medical         (c1 esterase, inhib, recombinant)       PNH       Medical         Soliris       PNH       Medical         (eculizumab)       aHUS       Myasthenia Gravis         NMOSD       NMOSD         Spinraza       Spinal muscle atrophy       Medical         (nusinersen)       Treatment resistant depression       Pharmacy         (esketamine)       Pharmacy         Strensiq       Hypophosphatasia       Pharmacy         (asfotase alfa)       Tepezza       Thyroid eye disease       Medical         Ultomiris       PNH       Medical	(vestronidase-Alfa)	Sly syndrome	
(metreleptin)       Nagalzyme       MPS VI       Medical         (galsulfase)       Maroteaux-Lamy syndrome         Nucala       Mod to severe asthma       Pharmacy         (mepolizumab)       Pharmacy         Ruconest       Hereditary angioedema       Medical         (c1 esterase, inhib, recombinant)       PNH       Medical         Soliris       PNH       Medical         (eculizumab)       aHUS       Myasthenia Gravis         NMOSD       NMOSD         Spinraza       Spinal muscle atrophy       Medical         (nusinersen)       Treatment resistant depression       Pharmacy         (esketamine)       Pharmacy         Strensiq       Hypophosphatasia       Pharmacy         (asfotase alfa)       Tepezza       Thyroid eye disease       Medical         Ultomiris       PNH       Medical	Myalent	Lipodystrophy	Pharmacy
Nagalzyme (galsulfase) Medical (galsulfase) Maroteaux-Lamy syndrome  Nucala Mod to severe asthma Pharmacy (mepolizumab)  Ruconest Hereditary angioedema Medical (c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab) AHUS Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical		Lipodystrophry	Filailliacy
(galsulfase)  Maroteaux-Lamy syndrome  Nucala (mepolizumab)  Ruconest (c1 esterase, inhib, recombinant)  Soliris (eculizumab)  Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical  Treatment resistant depression  Spravato (esketamine)  Strensiq (asfotase alfa)  Hereditary angioedema Medical  Medical  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical	(meneropun)		
(galsulfase)  Maroteaux-Lamy syndrome  Nucala (mepolizumab)  Ruconest (c1 esterase, inhib, recombinant)  Soliris (eculizumab)  Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical  Treatment resistant depression  Spravato (esketamine)  Strensiq (asfotase alfa)  Hereditary angioedema Medical  Medical  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical  Pharmacy  Medical	Nagalzyme	MPS VI	Medical
Ruconest Hereditary angioedema Medical (c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab) aHUS Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical	(galsulfase)	Maroteaux-Lamy syndrome	
Ruconest Hereditary angioedema Medical (c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab) aHUS Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical			
Ruconest (c1 esterase, inhib, recombinant)  Soliris PNH Medical  (eculizumab) aHUS  Myasthenia Gravis  NMOSD  Spinraza Spinal muscle atrophy Medical  (nusinersen)  Treatment resistant depression Pharmacy  (esketamine)  Strensiq Hypophosphatasia Pharmacy  (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical		Mod to severe asthma	Pharmacy
(c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab) aHUS  Myasthenia Gravis  NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical	(mepolizumab)		
(c1 esterase, inhib, recombinant)  Soliris PNH Medical (eculizumab) aHUS  Myasthenia Gravis  NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical		11 19	NA II
Soliris PNH Medical (eculizumab) aHUS Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical		Hereditary angioedema	Medical
Soliris PNH Medical  (eculizumab) aHUS  Myasthenia Gravis  NMOSD  Spinraza Spinal muscle atrophy Medical  (nusinersen)  Treatment resistant depression Pharmacy  (esketamine)  Strensiq Hypophosphatasia Pharmacy  (asfotase alfa)  Tepezza Thyroid eye disease Medical  (teprotumumab)  Ultomiris PNH Medical			
(eculizumab)     aHUS       Myasthenia Gravis     NMOSD       Spinraza     Spinal muscle atrophy     Medical       (nusinersen)     Treatment resistant depression     Pharmacy       (esketamine)     Pharmacy       Strensiq     Hypophosphatasia     Pharmacy       (asfotase alfa)     Thyroid eye disease     Medical       Ultomiris     PNH     Medical	recombinant)		
Myasthenia Gravis NMOSD  Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical	Soliris	PNH	Medical
Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical	(eculizumab)		
Spinraza Spinal muscle atrophy Medical (nusinersen)  Treatment resistant depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical		Myasthenia Gravis	
(nusinersen)  Treatment resistant depression Pharmacy  (esketamine)  Strensiq (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical		NMOSD	
(nusinersen)  Treatment resistant depression Pharmacy  (esketamine)  Strensiq (asfotase alfa)  Tepezza Thyroid eye disease Medical  Ultomiris PNH Medical	Caianas	Coin al pays als atmosphy	Madiaal
Spravato depression Pharmacy  (esketamine)  Strensiq Hypophosphatasia Pharmacy  (asfotase alfa)  Tepezza Thyroid eye disease Medical  (teprotumumab)  Ultomiris PNH Medical		Spinal muscle alrophy	iviedicai
Spravato depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical	(nusinersen)		
Spravato depression Pharmacy (esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical		Treatment resistant	
(esketamine)  Strensiq Hypophosphatasia Pharmacy (asfotase alfa)  Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical	Spravato		Pharmacy
(asfotase alfa)  Tepezza Thyroid eye disease Medical  (teprotumumab)  Ultomiris PNH Medical			
(asfotase alfa)  Tepezza Thyroid eye disease Medical  (teprotumumab)  Ultomiris PNH Medical			
Tepezza Thyroid eye disease Medical (teprotumumab)  Ultomiris PNH Medical		Hypophosphatasia	Pharmacy
(teprotumumab)  Ultomiris PNH Medical	(astotase alfa)		
(teprotumumab)  Ultomiris PNH Medical			
(teprotumumab)  Ultomiris PNH Medical	Tenezza	Thyroid eye disease	Medical
Ultomiris PNH Medical		Trigioid Cyc disease	IVICUICAI
	(toproturnama)		
(ravulizumab-cwyz)	Ultomiris	PNH	Medical
· · · · · · · · · · · · · · · · · · ·	(ravulizumab-cwyz)		

Providers' News / June 2020 (Page 16 of 36)

Vimizim	MPS IV	Medical
(elosulfase alfa)	Morquio A	
Yescarta	Cancers	Medical
(axicabtagene ciloleucel)		*Reviewed by Transplant Coordinator
Xolair	Mod to severe asthma	Medical & Pharmacy
(omalizumab)	Urticaria	
Zolgensma	Spinal muscle atrophy	Medical
(onasmnogene abeparvovec-		
XIOI)		
Zulresso	Postpartum depression	Medical
(brexanolone)		

For more information on how to submit a request for prior approval of one of these medications, call the appropriate customer service phone number on the back of the member ID card.

Customer service will direct callers to the prior approval form specific to the member's group. BlueAdvantage members can find the form at the following link:

https://www.blueadvantagearkansas.com/providers/forms.aspx.

For all other members, the appropriate prior approval form can be found at the following link: <a href="https://www.arkansasbluecross.com/providers/resource-center/provider-forms">https://www.arkansasbluecross.com/providers/resource-center/provider-forms</a>.

These forms and any additional documentation should be faxed to 501-210-7051 for BlueAdvantage members. For all other members, the appropriate fax number is 501-378-6647.

Providers' News / June 2020 (Page 17 of 36)

### National drug codes required

## Notice of Material Amendment to Arkansas Blue Cross and Blue Shield, Blue Advantage Administrators of Arkansas and Health Advantage lines of business

Effective October 1, 2020, National Drug Codes (NDC) must be included along with all drug codes being submitted on institutional and professional claims (837I and 837P). This will usually include all J codes but will apply to all drug codes being submitted for reimbursement. This requirement is for all Arkansas Blue Cross and Blue Shield, Blue Advantage Administrators of Arkansas and Health Advantage lines of business. This has already been required by the Blue Federal Employee Plan. Failure to include a correct NDC in the appropriate format will result in the claim being rejected back to the provider.

#### Instructions for an electronic claim

The following loops/segments will be required when filing 837 Professional & Institutional Claims when a drug code is present on a claim:

Loop 2410 = NDC

Segments:

LIN02 = N4 qualifier

LIN03 = NDC code quantity

Unit of Measure

#### Instructions for a paper claim\*

Block 24 — Supplemental Information: The following are types of supplemental information that can be entered in the shaded areas of Item Number 24.

National Drug Codes (NDC) for drugs – must have N4 qualifier followed by 11 digit NDC code. Do not put a space between the qualifier and code; do not use hyphens in the code.

Placing the following information in the shaded areas as shown on the NUCC site should be as "FYI" only since the data may not image properly. Arkansas Blue Cross does not recommend the use of this free form line. However, if it is used, it is critical that the right qualifiers be used.

\*Reprinted from p. 17 in the June 2007 issue of *Providers' News* 

## Standard formulary changes effective July 1, 2020

#### **Additions**

Product	Therapeutic Category/ Subcategory	Options/Comments
Baqsimi (glucagon) intranasal powder	Endocrine and Metabolic/ Glucose Elevating Agents	To provide an additional option for the treatment of severe hypoglycemia.
Bryhali (halobetasol propionate) topical lotion	Topical/ Dermatology/ Corticosteroids/ High Potency	To provide an additional topical option for the treatment of plaque psoriasis.
Emgality 100 mg/mL (galcanezumab-gnlm) subcutaneous solution for injection	Central Nervous System/ Migraine/ Preventive Migraine Agents/ Monoclonal Antibodies	To provide an option for the treatment of cluster headaches.
Nurtec ODT (rimegepant) orally disintegrating tablet	Central Nervous System/ Migraine/ Acute Migraine Agents/ Newer Agents	To provide an additional option for the acute treatment of migraine headaches.
Onexton (clindamycin- benzoyl peroxide) topical gel	Topical/ Dermatology/ Acne/ Topical	To provide an additional option for the topical treatment of acne.
Praluent (alirocumab) subcutaneous solution for injection	Cardiovascular/ Antilipemics/ PCSK9 Inhibitors	To provide an option for secondary prevention of cardiovascular events and high cholesterol.
Reyvow (lasmiditan) oral tablet	Central Nervous System/ Migraine/ Acute Migraine Agents/ Newer Agents	To provide an additional option for the acute treatment of migraine headaches.

Providers' News / June 2020 (Page 19 of 36)

Product	Therapeutic Category/ Subcategory	Options/Comments
Rybelsus (semaglutide) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Incretin Mimetic Agents	To provide an additional option to improve glycemic control in adults with type 2 diabetes mellitus.
Symjepi (epinephrine) intramuscular/ subcutaneous solution for injection	Respiratory/ Anaphylaxis Treatment Agents	To provide an additional option for the emergency treatment of allergic reactions.
Symtuza (darunavir- cobicistat-emtricitabine- tenofovir alafenamide) oral tablet	Anti-Infectives/ Antiretroviral Agents/ Antiretroviral Combinations	To provide an additional combination option for the treatment of HIV-1.
Ubrelvy (ubrogepant) oral tablet	Central Nervous System/ Migraine/ Acute Migraine Agents/ Newer Agents	To provide an additional option for the acute treatment of migraine headaches.
Vumerity (diroximel fumarate delayed-rel) oral delayed-release capsule	Central Nervous System/ Multiple Sclerosis Agents	To provide an additional option for the treatment of relapsing forms of multiple sclerosis.
Yupelri (revefenacin) inhalation solution	Respiratory/ Anticholinergics	To provide an additional option for the maintenance treatment of COPD.

### Medications moving to a higher tier

Product	Therapeutic Category/ Subcategory	Options/Comments
Apriso (mesalamine ext-rel) oral extended-release capsule	Gastrointestinal/ Inflammatory Bowel Disease/ Oral Agents	Preferred options include balsalazide, mesalamine delayed- rel caps, mesalamine delayed-rel tabs, mesalamine ext-rel caps, sulfasalazine, sulfasalazine delayed-rel, Azulfidine (sulfasalazine), Azulfidine EN-tabs (sulfasalazine delayed- rel), and Pentasa (mesalamine ext-rel caps).

Providers' News / June 2020 (Page 20 of 36)

Product	Therapeutic Category/ Subcategory	Options/Comments
Celebrex (celecoxib) oral capsule	Analgesics/ COX-2 Inhibitors	The preferred option is celecoxib.
Daypro (oxaprozin) oral tablet	Analgesics/ NSAIDs	Preferred options include diclofenac sodium delayed-rel, diflunisal, etodolac, ibuprofen, meloxicam, nabumetone, naproxen sodium, naproxen sodium tabs, naproxen tabs, oxaprozin, sulindac, Advil (ibuprofen), and Aleve (naproxen sodium).
<b>Dilaudid</b> (hydromorphone) oral liquid, oral tablet	Analgesics/ Opioid Analgesics	Preferred options include hydrocodone-acetaminophen, hydromorphone, morphine, oxycodone caps and tabs 5 mg, oxycodone concentrate 20 mg/mL, oxycodone tabs 15 mg and 30 mg, oxycodone solution 5 mg/5 mL, oxycodone-acetaminophen 5/325, and Nucynta (tapentadol).
Esgic (butalbital- acetaminophen- caffeine tabs) oral tablet	Analgesics/ Non-Opioid Analgesics	Preferred options include butalbital-acetaminophen-caffeine tabs and butalbital-aspirin-caffeine.
Fiorinal (butalbital- aspirin-caffeine) oral capsule	Analgesics/ Non-Opioid Analgesics	Preferred include butalbital-acetaminophen-caffeine tabs and butalbital-aspirin-caffeine.
Isordil (isosorbide dinitrate) oral tablet	Cardiovascular/ Nitrates/ Oral	Preferred options include isosorbide dinitrate oral, isosorbide mononitrate, and isosorbide mononitrate ext-rel.
Kadian (morphine ext- rel)	Analgesics/ Opioid Analgesics	Preferred options include fentanyl transdermal, hydromorphone ext-rel, methadone, morphine ext-rel,

Providers' News / June 2020 (Page 21 of 36)

Product	Therapeutic Category/ Subcategory	Options/Comments
oral extended-release capsule		Nucynta ER (tapentadol ext-rel), and Xtampza ER (oxycodone ext-rel).
Mobic (meloxicam) oral tablet	Analgesics/ NSAIDs	Preferred options include diclofenac sodium delayed-rel, diflunisal, etodolac, ibuprofen, meloxicam, nabumetone, naproxen sodium, naproxen sodium tabs, naproxen tabs, oxaprozin, sulindac, Advil (ibuprofen), and Aleve (naproxen sodium).
MS Contin (morphine ext-rel) oral extended-release tablet	Analgesics/ Opioid Analgesics	Preferred options include fentanyl transdermal, hydromorphone ext-rel, methadone, morphine ext-rel, Nucynta ER (tapentadol ext-rel), and Xtampza ER (oxycodone ext-rel).
Norco (hydrocodone- acetaminophen) oral tablet	Analgesics/ Opioid Analgesics	Preferred options include hydrocodone-acetaminophen, hydromorphone, morphine, oxycodone caps and tabs 5 mg, oxycodone concentrate 20 mg/mL, oxycodone tabs 15 mg and 30 mg, oxycodone solution 5 mg/5 mL, oxycodone-acetaminophen 5/325, and Nucynta (tapentadol).
NuvaRing (ethinyl estradiol-etonogestrel) vaginal ring	Endocrine and Metabolic/ Contraceptives/ Vaginal	The preferred option is ethinyl estradiol-etonogestrel.
Roxicodone (oxycodone tabs 15 mg, 30 mg) oral tablet	Analgesics/ Opioid Analgesics	Preferred options include hydrocodone-acetaminophen, hydromorphone, morphine, oxycodone caps and tabs 5 mg, oxycodone concentrate 20 mg/mL, oxycodone tabs 15 mg and 30 mg, oxycodone solution 5 mg/5 mL, oxycodone-acetaminophen 5/325, and Nucynta (tapentadol).
Sensipar (cinacalcet) oral tablet	Endocrine and Metabolic/ Calcium Receptor Antagonists	The preferred option is cinacalcet.
Uloric (febuxostat) oral tablet	Analgesics/ Gout	The preferred option is allopurinol.

(Page 22 of 36) Providers' News / June 2020

Product	Therapeutic Category/ Subcategory	Options/Comments
Ultram (tramadol) oral tablet	Analgesics/ Opioid Analgesics	Preferred options include tramadol (except NDC 52817019610) and tramadol ext-rel.
<b>Zyloprim</b> (allopurinol) oral tablet	Analgesics/ Gout	The preferred option is allopurinol.

#### Medications no longer covered

Product	Therapeutic Category/ Subcategory	Options/Comments
BRANDS		
Consensi (amlodipine- celecoxib) oral tablet	Cardiovascular/ Calcium Channel Blocker / Nonsteroidal Anti- Inflammatory Drug (NSAID) Combinations	Preferred options include amlodipine <b>WITH</b> celecoxib.
Norgesic Forte (orphenadrine-aspirin- caffeine) oral tablet	Central Nervous System/ Musculoskeletal Therapy Agents	Preferred options include carisoprodol, chlorzoxazone, cyclobenzaprine (except 7.5 mg tablet), metaxalone, methocarbamol, Robaxin (methocarbamol), and Skelaxin (metaxalone).
Repatha (evolocumab) subcutaneous solution for injection	Cardiovascular/ Antilipemics/ PCSK9 Inhibitors	The preferred option is Praluent (alirocumab).
Treximet (sumatriptan- naproxen sodium) oral tablet	Central Nervous System/ Migraine/ Selective Serotonin Agonist / Nonsteroidal Anti-inflammatory Drug (NSAID) Combinations	Preferred options include diclofenac sodium delayed-rel, diflunisal, etodolac, ibuprofen, naproxen sodium, naproxen sodium tabs, naproxen tabs, Advil (ibuprofen), or Aleve (naproxen sodium) <b>WITH</b> eletriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan injection, sumatriptan nasal spray, zolmitriptan, Imitrex (sumatriptan), Maxalt (rizatriptan), Nurtec ODT (rimegepant), Onzetra Xsail (sumatriptan nasal powder), Relpax (eletriptan), Reyvow (lasmiditan), Ubrelvy

Providers' News / June 2020 (Page 23 of 36)

Product	Therapeutic Category/ Subcategory	Options/Comments
		(ubrogepant), Zembrace SymTouch (sumatriptan injection), Zomig (zolmitriptan), or Zomig Nasal Spray (zolmitriptan).
GENERICS REMOV	ED DUE TO HYPER-IN	NFLATED COST
bimatoprost 0.03% ophthalmic solution	Topical/ Ophthalmic/ Prostaglandins	Preferred options include latanoprost, travoprost, Lumigan (bimatoprost), Travatan Z (travoprost), and Xalatan (latanoprost).
bupropion ext-rel tablet 450 mg oral extended-release tablet	Central Nervous System/ Antidepressants/ Miscellaneous Agents	Preferred options include bupropion, bupropion ext-rel (except bupropion ext-rel tablet 450 mg), Wellbutrin SR (bupropion ext-rel), and Wellbutrin XL (bupropion ext-rel).
chlorzoxazone 375 mg and 750 mg oral tablet	Central Nervous System/ Musculoskeletal Therapy Agents	Preferred options include carisoprodol, chlorzoxazone, cyclobenzaprine (except 7.5 mg tablet), metaxalone, methocarbamol, Robaxin (methocarbamol), and Skelaxin (metaxalone).
clindamycin gel 1% (NDC 68682046275 only) topical gel	Topical/ Dermatology/ Acne/ Topical	Preferred options include adapalene, adapalene-benzoyl peroxide, benzoyl peroxide, clindamycin gel (except NDC 68682046275), clindamycin lotion, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin gel 2%, erythromycin solution, erythromycin-benzoyl peroxide, sulfacetamide lotion 10%, tazarotene, tretinoin, tretinoin – Avita, tretinoin gel microsphere, Benzac AC (benzoyl peroxide), Benzamycin (erythromycin-benzoyl peroxide), Cleocin T (clindamycin gel/lotion/solution), Epiduo (adapalene-benzoyl peroxide), Epiduo Forte (adapalene-benzoyl peroxide), Klaron (sulfacetamide lotion 10%), Onexton (clindamycin-benzoyl peroxide), Retin-A (tretinoin), and Tazorac (tazarotene).

Health Advantage and BlueAdvantage Administrators of Arkansas are affiliates of the Arkansas Blue Cross and Blue Shield family of companies.

All are independent licensees of the Blue Cross Blue Shield Association.

(Page 24 of 36) Providers' News / June 2020

Product	Therapeutic Category/ Subcategory	Options/Comments
CoreMino	Anti-Infectives/ Antibacterials/	Preferred options include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and
(minocycline ext-rel)	Tetracyclines	Vibramycin (doxycycline hyclate capsule).
oral extended-release tablet		
cyclobenzaprine ext-	Central Nervous System/ Musculoskeletal	Preferred options include carisoprodol, chlorzoxazone, cyclobenzaprine (except 7.5 mg tablet), metaxalone,
oral extended-release capsule	Therapy Agents	methocarbamol, Robaxin (methocarbamol), and Skelaxin (metaxalone).
doxycycline hyclate delayed-rel tablet 200 mg	Anti-Infectives/ Antibacterials/ Tetracyclines	Preferred options include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and Vibramycin (doxycycline hyclate capsule).
oral delayed-release tablet		
doxycycline hyclate tablet 50 mg (NDC 72143021160 only) oral tablet	Anti-Infectives/ Antibacterials/ Tetracyclines	Preferred options include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and Vibramycin (doxycycline hyclate capsule).
doxycycline hyclate tablet 75 mg and 150 mg	Anti-Infectives/ Antibacterials/ Tetracyclines	Preferred options include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and Vibramycin (doxycycline hyclate capsule).
doxycycline monohydrate capsule 75 mg and 150 mg	Anti-Infectives/ Antibacterials/ Tetracyclines	Preferred options include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and Vibramycin (doxycycline hyclate capsule).
oral capsule		
ergotamine-caffeine	Central Nervous	Preferred options include dihydroergotamine injection,
oral tablet	System/ Migraine/ Ergotamine Derivatives	eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, D.H.E. 45 (dihydroergotamine injection), Imitrex (sumatriptan), Maxalt (rizatriptan), Nurtec ODT (rimegepant), Onzetra Xsail (sumatriptan nasal powder), Relpax (eletriptan), Reyvow (lasmiditan), Ubrelvy

(Page 25 of 36) Providers' News / June 2020

Product	Therapeutic Category/ Subcategory	Options/Comments
		(ubrogepant), Zembrace SymTouch (sumatriptan injection), Zomig (zolmitriptan), and Zomig Nasal Spray (zolmitriptan).
flucytosine capsule 500 mg	Anti-Infectives/ Antifungals	The preferred option is fluconazole.
oral capsule		
fluoxetine tablet 60 mg oral tablet	Central Nervous System/ Antidepressants/ Selective Serotonin Reuptake Inhibitors (SSRIs)	Preferred options include citalopram, escitalopram, fluoxetine (except fluoxetine tablet 60 mg), paroxetine HCl, paroxetine HCl ext-rel, sertraline, Celexa (citalopram), Paxil (paroxetine HCl), Paxil CR (paroxetine HCl ext-rel), Trintellix (vortioxetine), Viibryd (vilazodone), and Zoloft (sertraline).
flurandrenolide lotion (NDC 24470092112 only) topical lotion	Topical/ Dermatology/ Corticosteroids/ Low Potency	Preferred options include alclometasone cream, ointment 0.05%; desonide cream, lotion, ointment 0.05%; fluocinolone acetonide solution 0.01%; hydrocortisone cream 2.5%; hydrocortisone cream, ointment 0.5%, 1%; hydrocortisone lotion 1%; Cortizone (hydrocortisone cream, ointment 0.5%, 1%); and DesOwen (desonide cream, lotion, ointment 0.05%).
hydrocortisone butyrate lipophilic cream 0.1% topical cream	Topical/ Dermatology/ Corticosteroids/ Medium Potency	Preferred options include betamethasone valerate cream, lotion, ointment 0.1%; desoximetasone cream, ointment 0.05%; fluocinolone acetonide cream, ointment 0.025%; fluticasone propionate cream, lotion 0.05%, ointment 0.005%; hydrocortisone butyrate cream, lotion, ointment, solution 0.1%; hydrocortisone valerate cream, ointment 0.2%; mometasone cream, lotion, ointment 0.1%; triamcinolone acetonide cream, lotion 0.025%; triamcinolone acetonide cream, lotion, ointment 0.1%; and Elocon (mometasone cream, lotion, ointment 0.1%).

(Page 26 of 36) Providers' News / June 2020

Product	Therapeutic Category/ Subcategory	Options/Comments
ketoprofen capsule 25 mg	Analgesics/ NSAIDs	Preferred options include diclofenac sodium delayed-rel, diflunisal, etodolac, ibuprofen, meloxicam, nabumetone, naproxen sodium, naproxen sodium tabs, naproxen tabs, oxaprozin, sulindac, Advil (ibuprofen), and Aleve (naproxen
oral capsule		sodium).
Lorzone (chlorzoxazone) oral tablet	Central Nervous System/ Musculoskeletal Therapy Agents	Preferred options include carisoprodol, chlorzoxazone, cyclobenzaprine (except 7.5 mg tablet), metaxalone, methocarbamol, Robaxin (methocarbamol), and Skelaxin (metaxalone).
minocycline ext-rel oral extended-release tablet	Anti-Infectives/ Antibacterials/ Tetracyclines	Preferred include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and Vibramycin (doxycycline hyclate capsule).
Mondoxyne NL (doxycycline monohydrate)	Anti-Infectives/ Antibacterials/ Tetracyclines	Preferred options include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and Vibramycin (doxycycline hyclate capsule).
oral capsule		
naproxen- esomeprazole oral delayed-release tablet	Analgesics/ NSAIDs, Combinations	Preferred options include diclofenac sodium delayed-rel, diflunisal, etodolac, ibuprofen, meloxicam, nabumetone, naproxen sodium, naproxen sodium tabs, naproxen tabs, oxaprozin, sulindac, Advil (ibuprofen), or Aleve (naproxen sodium) <b>WITH</b> esomeprazole delayed-rel, lansoprazole delayed-rel, omeprazole delayed-rel, pantoprazole delayed-rel, Dexilant (dexlansoprazole delayed-rel), or Prilosec (omeprazole delayed-rel).
Okebo (doxycycline monohydrate) oral capsule	Anti-Infectives/ Antibacterials/ Tetracyclines	Preferred options include doxycycline hyclate 20 mg, doxycycline hyclate capsule, minocycline, tetracycline, and Vibramycin (doxycycline hyclate capsule).
orphenadrine-aspirin- caffeine oral tablet	Central Nervous System/ Musculoskeletal Therapy Agents	Preferred options nclude carisoprodol, chlorzoxazone, cyclobenzaprine (except 7.5 mg tablet), metaxalone, methocarbamol, Robaxin (methocarbamol), and Skelaxin (metaxalone).
Orphengesic Forte (orphenadrine-aspirin- caffeine)	Central Nervous System/ Musculoskeletal Therapy Agents	Preferred options include carisoprodol, chlorzoxazone, cyclobenzaprine (except 7.5 mg tablet), metaxalone, methocarbamol, Robaxin (methocarbamol), and Skelaxin (metaxalone).

(Page 27 of 36) Providers' News / June 2020

Product	Therapeutic Category/ Subcategory	Options/Comments
oral tablet		
posaconazole delayed-rel oral delayed-release	Anti-Infectives/ Antifungals	Preferred options include fluconazole, itraconazole, and Diflucan (fluconazole).
tablet		
sumatriptan- naproxen sodium oral tablet	Central Nervous System/ Migraine/ Selective Serotonin Agonist / Nonsteroidal Anti-inflammatory Drug (NSAID) Combinations	Preferred options include diclofenac sodium delayed-rel, diflunisal, etodolac, ibuprofen, naproxen sodium, naproxen sodium tabs, naproxen tabs, Advil (ibuprofen), or Aleve (naproxen sodium) <b>WITH</b> eletriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan injection, sumatriptan nasal spray, zolmitriptan, Imitrex (sumatriptan), Maxalt (rizatriptan), Nurtec ODT (rimegepant), Onzetra Xsail (sumatriptan nasal powder), Relpax (eletriptan), Reyvow (lasmiditan), Ubrelvy (ubrogepant), Zembrace SymTouch (sumatriptan injection), Zomig (zolmitriptan), or Zomig Nasal Spray (zolmitriptan).
tramadol (NDC 52817019610 only) oral tablet	Analgesics/ Opioid Analgesics	Preferred options include tramadol (except NDC 52817019610) and tramadol ext-rel.
triamcinolone acetonide aerosol 0.2% topical spray	Topical/ Dermatology/ Corticosteroids/ Medium Potency	Preferred options include betamethasone valerate cream, lotion, ointment 0.1%; desoximetasone cream, ointment 0.05%; fluocinolone acetonide cream, ointment 0.025%; fluticasone propionate cream, lotion 0.05%, ointment 0.005%; hydrocortisone butyrate cream, lotion, ointment, solution 0.1%; hydrocortisone valerate cream, ointment 0.2%; mometasone cream, lotion, ointment 0.1%; triamcinolone acetonide cream, lotion 0.025%; triamcinolone acetonide cream, lotion, ointment 0.1%; and Elocon (mometasone cream, lotion, ointment 0.1%).

(Page 28 of 36) Providers' News / June 2020

#### **Other**

Product	Therapeutic Category/ Subcategory	Options/Comments
BRANDS		
Pataday (olopatadine) ophthalmic solution	Topical/ Ophthalmic/ Antiallergics	Previously-prescription (Rx) products have switched to over-the-counter (OTC) status.
GENERICS		
febuxostat oral tablet	Analgesics/ Gout	Product has a required Boxed Warning, as the U.S. Food and Drug Administration (FDA) has noted an increased risk of death upon comparison to allopurinol.  The preferred option is allopurinol.
ranitidine oral capsule, oral syrup, oral tablet	Gastrointestinal/ H2 Receptor Antagonists	Product has been withdrawn from the market due to investigations showing the increasing presence of contaminant N-Nitrosodimethylamine (NDMA) in some ranitidine products.  Preferred options include cimetidine, famotidine, Tagamet HB 200 (cimetidine), Pepcid (famotidine), and Pepcid AC (famotidine).

## Think twice before prescribing antibiotics for bronchitis

In the face of a COVID-19 pandemic and with the increased use of telemedicine, we must continue to be mindful of the overuse of antibiotics to treat bronchitis.

Bronchitis may or may not require an antibiotic as it can be both viral and bacterial. The most common pattern is for bronchitis to start as a viral infection, but bacterial bronchitis can follow a viral infection of the upper respiratory system, such as cold or flu. In fact, it is possible to have both viral and bacterial bronchitis at the same time.

All are independent licensees of the Blue Cross Blue Shield Association.

Providers' News / June 2020 (Page 29 of 36)

Acute bronchitis can come on suddenly as the tubes that carry air to your lungs become inflamed. Acute bronchitis can cause wheezing, chest tightness and shortness of breath. It usually lasts about 3–10 days, but can last as long as three weeks. The cough, however, can linger much longer. Acute bronchitis usually gets better on its own without the need for antibiotics.

The Centers for Disease Control and Prevention (CDC) website states that at least 30 percent of antibiotic courses are prescribed unnecessarily for acute respiratory conditions such as colds, bronchitis and sore throats that are caused by viruses. Additionally, the CDC states that antibiotic use is the most important modifiable driver of antibiotic resistance. Antibiotic-resistant infections lead to higher healthcare costs, poor health outcomes and more toxic treatment. Any time antibiotics are used, they can cause side effects and lead to antibiotic resistance. Antibiotic resistance is one of the most urgent threats to the public's health.

#### Each year in the United States, at least 2 million people get infected with antibiotic-resistant bacteria. At least 23,000 people die as a result.

Antibiotic stewardship is much needed for clinics and facilities that routinely provide treatment. Antibiotic stewardship is the effort to measure and improve how antibiotics are prescribed and used. Improving antibiotic prescribing involves implementing effective strategies to align them with evidence-based recommendations for diagnosis and management.

Providers should implement at least one policy or practice to improve antibiotic prescribing, assess whether it is working and modify as needed. Providers should also give educational resources to patients on antibiotic prescribing. Patients always should know to take their antibiotics exactly as prescribed.

Regardless of diagnosis, providers always should ask: Does this have an infection that will respond to antibiotics? For example, providers should not prescribe an antibiotic for acute bronchitis because antibiotics are not recommended as treatment. Ultimately, it is best to determine if a case of bronchitis is viral or bacterial before prescribing an antibiotic. In addition, data on antibiotic prescribing is now being tracked and reported in various quality measures.

This article was reprinted from the December 2018 issue of *Providers' News*.

## **HEDIS®** news

## Changes to the Controlling High Blood Pressure HEDIS® Measure reduces the need for medical record reviews

The Controlling High Blood Pressure (CBP) Healthcare Effectiveness Data and Information Set (HEDIS®) measure has been updated to assess patients ages 18-85\* who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90) during the last reading of the year. (\*Patients turning 86 on December 31, 2020 are excluded.)

Previous CBP HEDIS specifications required medical record reviews to determine if a patient's blood pressure was under control. Now, billing blood pressure Current Procedural Terminology (CPT®) Category II codes on each office visit claim along with a hypertensive condition will determine compliance.

When you add the correct CPT Category II and ICD-10 codes to your claims, medical records will not need to be collected for confirmation. This optimizes time and lessens the need for record keeping for providers.

To learn more about claims coding to reduce medical record reviews and other measure changes, view the CBP tip sheet. 2020 Tip Sheet Controlling High Blood Pressure

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). CPT Copyright 2018 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

## Two star measures support importance of statin therapy for patients with cardiovascular disease and diabetes

The Centers for Disease Control and Prevention estimates that adults with diabetes are 1.7 times more likely to die from cardiovascular disease than adults without diabetes. Additionally, almost two out of five people with diabetes who could benefit from statin therapy to lower their risk of future heart attack, stroke and related deaths were not prescribed one, according to the *Journal of the American College of Cardiology*.

To support the importance of statin therapy, the Centers for Medicare and Medicaid Services include two star measures aimed at the use of statin therapy. Please consider prescribing statins for your patients diagnosed with atherosclerotic cardiovascular disease and diabetes.

These tip sheets give more information about the use of statin therapy:

Statin Use in Persons with Diabetes (SUPD)

### FEP covers smoking cessation tools

The Tobacco Cessation Incentive Program is a benefit for FEP members covered by the Standard Option, Basic Option and FEP Blue Focus. The program includes an online health coach, free tobacco cessation drugs and the chance to earn wellness incentives.

We encourage you to let FEP members know about this program. Have them log on to <u>fepblue.org/tobacco</u>. You can also print and distribute the flyers on pages 33–36. Contact information for the Arkansas Tobacco Prevention and Cessation Program is 501-661-2953.

Our offices will be closed Friday, July 3, in observance of Independence Day.







#### YOU CAN DO IT.

If you're reading this, you or someone you know is ready to quit smoking. We know how hard it can be, so we're here to help by providing the right tools and resources to keep you motivated along the way.

The first step is joining the **Tobacco Cessation Incentive Program**. You'll get daily tips and support from the Online Health Coach, free tobacco cessation drugs and may be eligible to earn wellness incentives. Standard Option, Basic Option and FEP Blue Focus members can attend smoking and tobacco cessation classes at no charge when provided by Preferred providers.

This program also covers nicotine dependence from vapes and e-cigarettes as these are not safe alternatives to tobacco. We'll stick with you every step of the way while you work to kick your habit.

#### Here's how to join:

- Set a Quit Tobacco goal and then create a Quit Plan with the Online Health Coach¹
- 2. Get an Rx from your doctor for your eligible tobacco cessation drugs, including OTC products\*



## TOBACCO CESSATION DRUGS INCLUDE:

Prescription medications like Chantix, Nicotrol and Bupropion and over-thecounter (OTC) products\* like Nicorette Gum, NicoDerm CQ Patch and Commit Lozenges.

<sup>1</sup>FEP Blue Focus members do not need to complete the Quit Tobacco goal to participate in this program.

\*Requires a physician's prescription and must be filled at a Preferred retail pharmacy

## 5 TIPS TO STAY CONFIDENT AS YOU QUIT



- 1 Find other things to do.
  - From exercising to spending time with friends, it helps to stay busy. Engage in activities that get your mind off smoking.
- Avoid common smoking triggers.

  While these may vary for everyone, you'll want to stay away from people and situations that remind you of smoking.
- 3 Drink plenty of water.

  This not only rinses your mouth and flushes out the toxins, but it also keeps your mouth occupied.
- Make it public.
  - Telling at least one other person helps to hold you accountable. Other people can also provide much-needed support.
- Don't try to think too far ahead.
  Instead, reward yourself for each day that you're smoke-free.

#### **U.S. SMOKER STATS**







1 IN 5 DEATHS ARE RELATED TO SMOKING





#### NOW THE GOOD NEWS

**SMOKING IS DOWN SINCE 1997** 



**NEARLY** 1.3 MM SMOKERS **OUIT EVERY YEAR**  YOU COULD SAVE



\*Based on smoking one pack a day.

#### ONCE YOU QUIT SMOKING, YOU CAN LOOK FORWARD TO THESE HEALTH BENEFITS:



Carbon monoxide in blood stream drops to normal



Circulation and lung function improve; heart attack risk begins to drop

#### 20 MINUTES

#### 12 HOURS

3 DAYS

**2 12 WEEKS** 

Heart rate and blood pressure drop



Nicotine has left your body





Risk of coronary heart disease drops to that of a nonsmoker

#### 2 5 YEARS

Risk of mouth, throat, esophagus and bladder cancer cuts in half: risk of stroke reduces to that of a nonsmoker

15 YEARS



If you're ready to guit smoking, we're here to help. Learn more about the Tobacco Cessation Incentive Program and our Quit with Blue resources at fepblue.org/tobacco.

Sources: The U.S. Department of Health and Human Services, CDC, Smokefree.gov.

This information is not meant to substitute the advice of your doctor or any other healthcare professional. You should speak to your doctor before starting a new diet or exercise routine.

This is a summary of the features of the Blue Cross and Blue Shield Service Benefit Plan. Before making a final decision, please read the Plan's Federal brochures (Standard Option and Basic Option: RI 71-005; FEP Blue Focus: RI 71-017). All benefits are subject to the definitions, limitations and exclusions set forth in the Federal brochures.

The Blue Cross and Blue Shield Service Benefit Plan complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

Para obtener asistencia en español, llame al servicio de atención al cliente al número que aparece en su tarjeta de identificación.

請撥打您ID卡上的客服號碼以尋求中文協助。 TCIPQRG2020



## Smoking is an addictive habit that can be challenging to kick.

Studies prove you're more likely to successfully quit tobacco if you are being coached. The Arkansas Tobacco Quitline is funded by Tobacco Settlement dollars, so you never have to pay for the service, which includes:

Free unlimited Web coaching

Free personalized phone sessions with a Quit Coach®

Free quit guides

Free Arkansas Diabetes Resources and Educational Materials

Your choice of free medication mailed directly to your home

Smoking directly affects your health, and when you already have one health hurdle, why stack the deck against yourself with more?

Arkansas Tobacco Prevention and Cessation Program 4815 West Markham, Slot 3 Little Rock, AR 72205 (501) 661-2953

Arkansas Diabetes Prevention and Control Section Chronic Disease Branch 4815 W. Markham St., Slot 6 Little Rock, AR 72203 (501) 661-2627

Arkansas Tobacco Quitline
1-800-QUIT-NOW
1 800 784 8669
Open seven days a week
7 a.m. – 2 a.m.
Free medications, while supplies last

Services are available in English Spanish, Marshallese and more than 160 other languages.



Tob cco ettlemen Doll r t

# One More Reason TO QUIT


Diabetes and Tobacco Use

1-800-QUIT-NOW









## What is diabetes?

Diabetes happens when the body stores unhealthy amounts of glucose (sugar) in the blood. The hormone insulin helps remove glucose (sugar) from the bloodstream to cells in the body. Diabetes happens when your body does not get enough insulin, or does not use insulin they way it should. Diabetes can cause serious health complications including heart disease, blindness, kidney failure and lower-extremity amputations.



- IF YOU ARE A PERSON LIVING WITH DIABETES, YOU CAN PUT YOUR HEALTH AT GREATER RISK BY CHOOSING TO SMOKE OR USE TOBACCO PRODUCTS.
- SMOKING RAISES BLOOD SUGAR LEVELS AND MAKES IT HARDER TO CONTROL YOUR DIABETES.
- YOUR MEDICATIONS AND INSULIN SHOTS MAY NOT WORK AS WELL BECAUSE YOU SMOKE
- YOU COULD DEVELOP PROBLEMS SUCH AS HIGH BLOOD PRESSURE, A HEART ATTACK AND STROKE.
- SMOKING DAMAGES BLOOD VESSELS, WHICH CAN INCREASE YOUR CHANCES OF INFECTIONS LIKE FOOT ULCERS.
- SOME SMOKERS LIVING WITH DIABETES HAVE THEIR TOES, LEGS AND FEET REMOVED (AMPUTATIONS) BECAUSE SMOKING DECREASES BLOOD FLOW TO INFECTED BODY PARTS.
- SMOKING CAN CAUSE EYE, KIDNEY AND NERVE PROBLEMS.

## Make a Plan to Quit

#### **SET YOUR QUIT DAY**

When you call the Arkansas Tobacco Quitline, you will be in charge of setting your own quit date. Pick one and mark it on every calendar you own.

#### **GET PREPARED**

Quitting can be challenging, but if you remove all temptations and reminders, it will be easier. Throw away cigarettes, lighters and ashtrays. Replace these with healthy snacks like raw vegetables and stress balls to give your hands something to do.

